 |
19 Feb 2026
Developer of optical pulse oximetry devices for blood oxygen monitoring to join Danaher's diagnostics segment.
Danaher, the NYSE-listed biotechnology and diagnostics company, is to acquire Masimo Corporation, the California-based firm best known for its development of optical pulse oximetry devices widely used in hospitals to monitor blood oxygenation in patients.
The near-$10 billion deal brings to a close a tumultuous period for Masimo that saw the company part ways with founder-CEO Joe Kiani and sell its non-healthcare business in audio technology, but also win more than $600 million in damages from Apple for patent infringement.
Expansion plans
The two firms say that Masimo will become a standalone business unit and brand within Danaher’s “diagnostics” unit, and will operate autonomously.
Masimo’s current CEO Katie Szyman said: “We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring. Danaher shares our commitment to investing in talent and innovation and will be an ideal fit to help power the next chapter of Masimo.
“Importantly, becoming part of Danaher’s Diagnostics segment will strengthen our ability to scale our monitoring technologies globally and accelerate our mission of delivering Masimo innovations that empower clinicians to transform patient care.”
Danaher’s CEO Rainer Blair added: “We've followed this innovative company for many years and see it as an exceptional strategic fit for Danaher.
“Masimo is a leader in pulse oximetry and other patient monitoring solutions, which combined with its trusted brand and differentiated technology, will greatly strengthen our diagnostics franchise.
“With the Danaher Business System and our global scale, we see opportunities to expand Masimo's reach and continue improving outcomes for patients, particularly those in acute care settings."
Diagnostics business unit
News of the agreement sent Masimo’s Nasdaq-listed stock price up in value by more than 30 per cent, with the $180-per-share purchase price last achieved just under a year ago.
During their most recent financial update, Masimo’s executive team indicated that the company would likely post sales revenues of just over $1.5 billion in its full-year 2025 results due next week, down from the $2 billion figure for 2024 that also included the non-healthcare audio business.
Danaher said that under its ownership, Masimo is expected to generate annual earnings before interest, tax, depreciation and amortization (EBITDA) of more than $530 million by 2027.
The parent company, which is renowned for its attention to operating efficiencies, says that it expects to realize more than $125 million in cost savings within five years of the acquisition closing, which is currently expected to happen by the end of this year.
Joining Danaher’s diagnostics business unit will see the firm come under the same corporate umbrella as Beckman Coulter, pathology specialist Leica Biosystems, and point-of-care blood diagnostics firms HemoCue and Radiometer, as well as molecular testing expert Cepheid, and breast biopsy pioneer Mammotome.
 |  |  |  |  |  |  |
| © 2026 SPIE Europe |
|
